Project Grant R44DK096715

This federal Project Grant award of $293,604 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to understand the role of the hypothalamic adhesion G-protein coupled receptor L 1 (ADGRL1) in counteracting hypoglycemia (dangerously low blood glucose levels). The primary research aims are to: 1) Establish the contribution of ADGRL1 in the ventromedial nucleus of the hypothalamus...

Federal Grant Award Summary The University of Michigan received a $780,220 Project Grant award dated February 27, 2026, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports a clinical optimization trial to evaluate the effectiveness of two scalable digital behavioral intervention components for mitigating Level 2 hypoglycemia (severe low blood glucose)...

The University of Texas Health Science Center at San Antonio received a $775,865 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 10, 2025, with completion targeted for July 31, 2030. This research initiative investigates glucagon-mediated glycemic effects in patients who have undergone bariatric surgery procedures, specifically gastric...

Federal Grant Award Summary Integrated Medical Sensors Inc. received a $569,998 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 1, 2025, with completion targeted for July 31, 2026. The grant funds the development and validation of optimized data processing algorithms for real-time glucose monitoring on the company's proprietary...

Federal Grant Award Summary Persista Bio Inc. received a $287,250 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) awarded on September 11, 2025. The award funds the development and manufacturing of a clinical-grade cell capsule for the O2LINE Implant System, an advanced oxygenated cell encapsulation device designed to treat Type 1 Diabetes (T1D) without...

Federal Cooperative Agreement Summary The University of California, San Diego received a $2.26 million Cooperative Agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 11, 2025, with completion targeted for August 31, 2028. This award funds a clinical research study investigating the safe use of sodium-glucose cotransporter inhibitors (SGLTIs)...

Federal Grant Award Summary Persista Bio Inc. received a $2.19 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on September 8, 2025, with a completion date of August 31, 2027. The award funds advanced preclinical development of the O2LINE System, a safe, anti-fibrotic, high-capacity, oxygenated cell encapsulation device designed for Type...

Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Virginia a $788,831 Project Grant effective February 1, 2026, through December 31, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds the development of a ketone-aware automated insulin delivery (AID) system designed to enable safe use of sodium-glucose cotransporter inhibitors (SGLT-I) in people with...

Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $183,452 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 21, 2025 through August 31, 2028. This award funds a real-world comparative safety study of insulin glargine-yfgn (Semglee), the first interchangeable biosimilar insulin approved by the FDA in...

Federal Project Grant Award Summary The Regents of the University of Minnesota received a $308,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective February 1, 2026, with a completion date of December 31, 2028. This pilot clinical trial investigates the efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor therapy in islet...